Drug Trial Radar · NCT03145220
Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)
Last checked: Nov 19, 2026Latest source record: Jun 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
180
Actual
Start
Jun 2016
Primary completion
Oct 2018
Study completion Oct 2018
Sponsor
- Lead sponsor
- Radboud University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Exponential Biotherapies Inc.
- First posted
- May 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
EA-230 is a newly developed synthetic compound with anti-inflammatory properties, it is a linear tetrapeptide derived from the human chorionic gonadotropin hormone (hCG). Recently, its immunomodulatory effects in humans were confirmed in a phase I trial and an optimal dose was established. To establish this anti-inflammatory effect in a selected patient population and assess clinical outcome, a combined phase IIa/IIb trial will be conducted with patients undergoing cardiac surgery.
Conditions
- Systemic Inflammatory Response Syndrome
- Coronary Artery Bypass Grafting
Interventions
EA-230Drug
Active intervention
Placebo (NaCl)Other
Placebo intervention
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability (treatment related (serious) adverse events)Time frame: Total (serious) adverse events related to treatment at day 90 after treatment
- Interleukin-6 (IL-6)Time frame: 1 day: at baseline, start of the cardiopulmonary bypass (CPB), stop of CPB, 2h after stop of CPB, 4h after stop of CPB, 6h after stop of CPB and first post-operative day.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Intensive care, research unit, Radboud University Medical Centre
Nijmegen, Gelderland, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.